IXI vs. TRX, COS, FUM, C4XD, DDDD, OKYO, AOR, AREC, OPTI, and POLB
Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), Futura Medical (FUM), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), AorTech International (AOR), Arecor Therapeutics (AREC), OptiBiotix Health (OPTI), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
IXICO vs.
IXICO (LON:IXI) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
IXICO has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
In the previous week, IXICO's average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.
Tissue Regenix Group has a net margin of -3.46% compared to IXICO's net margin of -31.10%. Tissue Regenix Group's return on equity of -2.87% beat IXICO's return on equity.
56.0% of IXICO shares are held by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are held by institutional investors. 30.3% of IXICO shares are held by company insiders. Comparatively, 47.3% of Tissue Regenix Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Tissue Regenix Group received 18 more outperform votes than IXICO when rated by MarketBeat users. However, 71.64% of users gave IXICO an outperform vote while only 69.53% of users gave Tissue Regenix Group an outperform vote.
Tissue Regenix Group has higher revenue and earnings than IXICO. Tissue Regenix Group is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.
Summary
Tissue Regenix Group beats IXICO on 10 of the 13 factors compared between the two stocks.
Get IXICO News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:IXI) was last updated on 3/31/2025 by MarketBeat.com Staff
Buy IXI Stock Free IXI Stock Alerts